Factors Likely to Affect the Uptake of Genomic Approaches to Cancer Screening in Primary Care: A Scoping Review
Authors:
- Kaitlyn V. DavisKDKaitlyn V. Davis
- Mie H. HallmanMHMie H. Hallman
- Melissa DiCarloMDMelissa DiCarlo
- Sophie M. WambuaSWSophie M. Wambua
- Rachel L. JaffeRJRachel L. Jaffe
- Allison W. WelshAWAllison W. Welsh
- Cameron KerberCKCameron Kerber
- Hushan YangHYHushan Yang
- Christopher V. ChambersCCChristopher V. Chambers
- Ronald E. MyersRMRonald E. Myers
Open Access
- 10 December 2022
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (12) , 2044
Abstract
Genomic tests are being developed for use in cancer screening. As most screening is offered in primary care settings, primary care provider and patient perceptions of such tests are likely to affect uptake. We conducted a scoping review to synthesize information on factors likely to affect patient and provider use of biospecimen collection and analysis for cancer screening, methods referred to as liquid biopsy or multi-cancer early detection (MCED) testing when used to detect multiple cancers. We ultimately identified 7 articles for review and analyzed them for major themes. None reported on primary care provider perspectives. Six articles focused on patient perceptions about testing for a single cancer (colorectal), and 1 reported on patient views related to testing for multiple cancers. Factors favoring this type of testing included its non-invasiveness, and the perceived safety, convenience, and effectiveness of testing. There is a dearth of information in the literature on primary care provider perceptions about liquid biopsy and MCED testing. The limited information on patient perceptions suggests that they are receptive to such tests. Research on primary care provider and patient test-related knowledge, attitudes, and behavior is needed to guide future implementation in primary care settings.Keywords
Funding Information
- Sidney Kimmel Cancer Center of Thomas Jefferson University (5P30CA056036-17)
- Exact Sciences Corporation (5P30CA056036-17)
This publication has 27 references indexed in Scilit:
- PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and ExplanationAnnals of Internal Medicine, 2018
- Primary care providers’ lived experiences of genetics in practiceJournal of Community Genetics, 2018
- Stool DNA-based versus colonoscopy-based colorectal cancer screening: patient perceptions and preferencesFamily Medicine and Community Health, 2015
- Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literatureGenetics in Medicine, 2015
- Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in GermanyBMC Gastroenterology, 2014
- Preferences for potential innovations in non-invasive colorectal cancer screening: A labeled discrete choice experiment for a Dutch screening campaignActa Oncologica, 2014
- Patient perceptions of stool DNA testing for pan-digestive cancer screening: A survey questionnaireWorld Journal of Gastroenterology, 2014
- Patient preferences for colorectal cancer screening: how does stool DNA testing fare?2007
- Colorectal Cancer Screening Using Stool DNA Analysis in Clinical Practice: Early Clinical Experience with Respect to Patient Acceptance and Colonoscopic Follow-up of Abnormal TestsClinical Colorectal Cancer, 2006
- Patient perceptions of stool-based DNA testing for colorectal cancer screeningAmerican Journal of Preventive Medicine, 2005